Medigene and bluebird partner for TCR immunotherapies; Deal expanded
Medigene AG and bluebird bio Inc. agreed to work together on the discovery and development of T-cell receptor (TCR) immunotherapies against four undisclosed cancer targets.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.